Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Background: Alopecia, an autoimmune condition characterized by hair loss, significantly impacts millions globally, often leading to psychological distress such as anxiety and depression. Current treatments are variably effective and frequently associated with adverse effects that restrict long-term use. This study evaluates the efficacy of Baricitinib, a Janus Kinase inhibitor, in treating severe alopecia, focusing on hair regrowth and patient-reported outcomes.
Methods: This research synthesized data from recent publications (2018-2023) including clinical trials, reviews, meta-analyses, and systematic reviews, sourced from databases such as PubMed, Springer, and Elsevier. The inclusion criteria focused on recent studies in English evaluating Baricitinib's effectiveness in severe alopecia cases. The primary outcome measures were the extent of hair regrowth and the change in patient-reported outcomes.
Results: The analysis included results from the BRAVE-AA1 and BRAVE-AA2 trials, which showed significant hair regrowth in patients as evidenced by improved Severity of Alopecia Tool (SALT) scores. Notably, patients treated with baricitinib demonstrated a marked percent change in SALT scores and a higher proportion achieving an absolute SALT score of ≤10 within 36 weeks compared to the placebo. The treatment was well-tolerated with minimal adverse effects reported.
Conclusion: Baricitinib has shown promising results in promoting significant hair regrowth in patients with severe alopecia, with minimal side effects, making it a viable treatment option. The FDA has approved Baricitinib for this indication. However, further research is necessary to evaluate the long-term safety of Baricitinib and to confirm these findings in a larger cohort.
Keywords
Alopecia, Autoimmune condition, Hair loss, Psychological distress, Anxiety, Depression, Baricitinib, Janus Kinase inhibitor, Severe alopecia, Hair regrowth, Treatment Outcome, Patient Satisfaction
Disciplines
Dermatology | Integumentary System | Medicine and Health Sciences | Pharmaceutical Preparations | Primary Care | Psychiatric and Mental Health | Psychiatry | Therapeutics
Document Type
Poster
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.134_2024
Included in
Dermatology Commons, Integumentary System Commons, Pharmaceutical Preparations Commons, Primary Care Commons, Psychiatric and Mental Health Commons, Psychiatry Commons, Therapeutics Commons
The Efficacy of Baricitinib as a Treatment Option for Alopecia, In Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes
Background: Alopecia, an autoimmune condition characterized by hair loss, significantly impacts millions globally, often leading to psychological distress such as anxiety and depression. Current treatments are variably effective and frequently associated with adverse effects that restrict long-term use. This study evaluates the efficacy of Baricitinib, a Janus Kinase inhibitor, in treating severe alopecia, focusing on hair regrowth and patient-reported outcomes.
Methods: This research synthesized data from recent publications (2018-2023) including clinical trials, reviews, meta-analyses, and systematic reviews, sourced from databases such as PubMed, Springer, and Elsevier. The inclusion criteria focused on recent studies in English evaluating Baricitinib's effectiveness in severe alopecia cases. The primary outcome measures were the extent of hair regrowth and the change in patient-reported outcomes.
Results: The analysis included results from the BRAVE-AA1 and BRAVE-AA2 trials, which showed significant hair regrowth in patients as evidenced by improved Severity of Alopecia Tool (SALT) scores. Notably, patients treated with baricitinib demonstrated a marked percent change in SALT scores and a higher proportion achieving an absolute SALT score of ≤10 within 36 weeks compared to the placebo. The treatment was well-tolerated with minimal adverse effects reported.
Conclusion: Baricitinib has shown promising results in promoting significant hair regrowth in patients with severe alopecia, with minimal side effects, making it a viable treatment option. The FDA has approved Baricitinib for this indication. However, further research is necessary to evaluate the long-term safety of Baricitinib and to confirm these findings in a larger cohort.